Phase 3 RCT in 654 women with HER2+ metastatic breast cancer on first-line maintenance trastuzumab/pertuzumab: adding tucatinib improved PFS vs placebo (median 24.9 vs 16.3 months; HR 0.641); diarrhoea in 72.7%, 6.1% grade ≥3.
RCTn = 654
Dieras et al. HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer